DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,832,800 | +6.3% | 346,816 | +3.1% | 0.16% | +1.3% |
| Q2 2023 | $80,771,500 | -9.8% | 336,465 | -5.1% | 0.16% | -18.5% |
| Q1 2023 | $89,578,420 | -5.8% | 354,696 | -0.9% | 0.20% | -10.1% |
| Q4 2022 | $95,115,238 | +2.9% | 357,943 | +0.0% | 0.22% | -12.5% |
| Q3 2022 | $92,443,000 | +4.6% | 357,941 | +2.7% | 0.25% | +8.8% |
| Q2 2022 | $88,403,000 | -14.3% | 348,453 | -0.8% | 0.23% | -0.9% |
| Q1 2022 | $103,118,000 | -14.0% | 351,295 | -3.5% | 0.23% | -12.5% |
| Q4 2021 | $119,851,000 | +53.3% | 364,107 | +41.6% | 0.26% | +25.8% |
| Q3 2021 | $78,168,000 | +6.4% | 257,157 | -6.1% | 0.21% | -1.9% |
| Q2 2021 | $73,458,000 | +22.9% | 273,870 | +3.4% | 0.21% | +12.7% |
| Q1 2021 | $59,753,000 | +5.2% | 264,861 | +3.6% | 0.19% | -20.3% |
| Q4 2020 | $56,790,000 | +14.6% | 255,672 | +11.2% | 0.24% | -0.8% |
| Q3 2020 | $49,549,000 | +52.9% | 229,868 | +25.6% | 0.24% | +35.0% |
| Q2 2020 | $32,396,000 | +29.3% | 183,067 | +1.3% | 0.18% | +9.3% |
| Q1 2020 | $25,058,000 | -8.8% | 180,642 | +1.0% | 0.16% | 0.0% |
| Q4 2019 | $27,474,000 | +1.7% | 178,925 | -4.4% | 0.16% | +10.2% |
| Q3 2019 | $27,011,000 | +3.0% | 187,216 | +2.0% | 0.15% | -5.8% |
| Q2 2019 | $26,230,000 | +57.5% | 183,463 | +45.5% | 0.16% | +40.5% |
| Q1 2019 | $16,656,000 | +30.2% | 126,084 | +1.1% | 0.11% | +13.3% |
| Q4 2018 | $12,790,000 | -3.6% | 124,706 | +1.8% | 0.10% | +2.1% |
| Q3 2018 | $13,270,000 | +10.3% | 122,551 | +0.3% | 0.10% | +2.1% |
| Q2 2018 | $12,035,000 | +23.0% | 122,188 | +22.0% | 0.09% | +14.6% |
| Q1 2018 | $9,782,000 | +7.0% | 100,187 | +1.6% | 0.08% | +9.3% |
| Q4 2017 | $9,145,000 | +5.1% | 98,616 | -3.0% | 0.08% | +1.4% |
| Q3 2017 | $8,704,000 | -21.4% | 101,659 | -22.6% | 0.07% | -25.3% |
| Q2 2017 | $11,067,000 | +16.9% | 131,332 | +18.6% | 0.10% | +8.8% |
| Q1 2017 | $9,468,000 | +32.2% | 110,747 | +20.3% | 0.09% | +16.7% |
| Q4 2016 | $7,161,000 | +29.8% | 92,078 | +30.9% | 0.08% | +21.9% |
| Q3 2016 | $5,518,000 | -12.6% | 70,329 | +12.3% | 0.06% | -20.0% |
| Q2 2016 | $6,316,000 | +9.4% | 62,620 | +2.7% | 0.08% | +321.1% |
| Q1 2016 | $5,774,000 | -7.1% | 60,946 | -8.7% | 0.02% | -74.3% |
| Q4 2015 | $6,213,000 | +35.1% | 66,738 | +23.8% | 0.07% | +21.3% |
| Q3 2015 | $4,599,000 | +208.0% | 53,899 | +209.1% | 0.06% | +154.2% |
| Q2 2015 | $1,493,000 | -41.3% | 17,439 | -41.8% | 0.02% | -36.8% |
| Q1 2015 | $2,542,000 | -5.9% | 29,944 | -4.9% | 0.04% | -7.3% |
| Q4 2014 | $2,700,000 | +16.6% | 31,499 | +3.4% | 0.04% | +5.1% |
| Q3 2014 | $2,315,000 | +34.0% | 30,463 | +38.8% | 0.04% | +30.0% |
| Q2 2014 | $1,727,000 | +5.0% | 21,940 | +0.1% | 0.03% | -6.2% |
| Q1 2014 | $1,644,000 | -11.8% | 21,923 | -9.2% | 0.03% | -15.8% |
| Q4 2013 | $1,863,000 | +31.8% | 24,139 | +18.4% | 0.04% | +8.6% |
| Q3 2013 | $1,414,000 | -1.5% | 20,394 | -10.1% | 0.04% | -10.3% |
| Q2 2013 | $1,436,000 | – | 22,682 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |